GlobeNewswire Inc | Jan 6, 2022 01:03PM EST

January 06, 2022

JERSEY CITY, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will present during two virtual investor conferences in January.

Presentation details:

-- LifeSci Partners 11th Annual Corporate Access EventFormat: Virtual panel discussion with CEO and 1:1 meetingsPanel Title: The Best of Both Worlds Defining Yourself When You Fit into More Than One BasketDate and Time: Friday, January 7, at 10:00 a.m. ETRegistration link:LifeSci Partners Corporate Access Event 2022

-- H.C. Wainwright Bioconnect 2022 Virtual Healthcare ConferenceFormat: Virtual event with webcast of corporate update presentation by Dr. TagliettiDate and Time: Presentation webcast will be available on-demand January 10-13 for event participantsRegistration link:H.C. Wainwright Bioconnect 2022

The latest SCYNEXIS investor presentation can be found on the corporate website here.

AboutSCYNEXIS

SCYNEXIS, Inc.(NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. We are developing our lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. The New Drug Application (NDA) for BREXAFEMME(ibrexafungerp tablets) was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2021. For more information, visitwww.brexafemme.com. We are also continuing late-stage clinical development of ibrexafungerp for the prevention of recurrent VVC as well as the treatment of life-threatening invasive fungal infections in hospitalized patients. For more information, visitwww.scynexis.com.

CONTACTInvestor RelationsIrina KofflerLifeSci AdvisorsTel: (646) 970-4681ikoffler@lifesciadvisors.com

Media RelationsGloria GasaaturaLifeSci CommunicationsTel: (646) 970-4688ggasaatura@lifescicomms.com